Cardiovascular Disease

SGS has performed 73 clinical pharmacology studies with anti-thrombotic, anti-hypertensive and anti-arrhythmic drug candidates since 2003.

Coagulation and Thrombosis
40 clinical trial protocols were carried for Coagulation and Thrombosis drugs. SGS offers a comprehensive type of clinical protocols covering the whole process of early clinical development programs.

Over the five last years we included more than 1500 healthy subjects in these coagulation and thrombosis trials. Our early clinical experience in this therapeutic area includes a wide range of  drug categories:

• Direct Thrombin Inhibitor
• Heparin, Unfractionated
• Low Molecular Weight Heparins
• Platelet Aggregation Inhibitors

A comprehensive list of methods are available for the assessment of the coagulation and platelet function

• Activating clotting time (ACT)
• Activating partial thromboplastin time (APTT)
• Prothrombin time (PT)
• Thrombin time
• Thrombin generation time
• Ex vivo-induced aggregation  
• Thromboelastometry (Rotem®)
• Platelet receptors by flow cytometry or RIA, perfusion chambers

Also are available a list of validated methods for the determination of biomarkers of coagulation.